アルクロフェナク

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P330：口をすすぐこと。

  P501：内容物/容器を．．．に廃棄すること。

アルクロフェナク 価格

アルクロフェナク 化学特性,用途語,生産方法

• 効能

  抗炎症薬

• 化学的特性

  Off-White to Pale Yellow Solid

• 使用

  Analgesic; antipyretic; anti-inflammatory.

• 定義

  ChEBI: An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and r sh.

• 世界保健機関（WHO）

  Alclofenac, a phenylacetic acid derivative with analgesic, antipyretic and antiinflammatory activity, was introduced in 1972 for the treatment of rheumatic disorders. In the late 1970s its use was associated with a high incidence of adverse effects, mainly skin rashes, and a urinary metabolite was reported to have mutagenic activity (positive Ames test). This resulted in the withdrawal of the drug, in some cases voluntarily, from several countries. In others registration has been refused. The reported mutagenic potential has been questioned by some investigators and the drug remains on the market in at least three countries with highly evolved regulatory authorities.

• Dosage

  Alclofenac when used at 3 g/d in the treatment of rheumatoid arthritis is as effective as 75 mg/d of indomethacin with fewer adverse effects. In the treatment of osteoarthritis 1500 mg/d is as effective and is better tolerated than 300 mg/d of phenylbutazone. Alclofenac has been withdrawn from the market in the United Kingdom because of skin rash and vasculitis (blood vessel inflammation).

アルクロフェナク 上流と下流の製品情報

アルクロフェナク 生産企業

Global(48)Suppliers

アルクロフェナク スペクトルデータ(¹HNMR)

22131-79-9, アルクロフェナク キーワード